Literature DB >> 26629432

Cons: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy?

Ursula Nestle1, José Belderbos1.   

Abstract

Entities:  

Year:  2015        PMID： 26629432      PMCID： PMC4630511          DOI： 10.3978/j.issn.2218-6751.2015.08.07

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  19 in total

1.  Radiation dose-effect relations and local recovery in perfusion for patients with non-small-cell lung cancer.

Authors:  Y Seppenwoolde; S H Muller; J C Theuws; P Baas; J S Belderbos; L J Boersma; J V Lebesque
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-06-01       Impact factor: 7.038

2.  Central-airway necrosis after stereotactic body-radiation therapy.

Authors:  Michael N Corradetti; Andrew R Haas; Ramesh Rengan
Journal:  N Engl J Med       Date:  2012-06-14       Impact factor: 91.245

3.  LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.

Authors:  S Adebahr; S Collette; E Shash; M Lambrecht; C Le Pechoux; C Faivre-Finn; D De Ruysscher; H Peulen; J Belderbos; R Dziadziuszko; C Fink; M Guckenberger; C Hurkmans; U Nestle
Journal:  Br J Radiol       Date:  2015-04-15       Impact factor: 3.039

4.  Local dose-effect relations for lung perfusion post stereotactic body radiotherapy.

Authors:  Alize E H Scheenstra; Maddalena M G Rossi; José S A Belderbos; Eugène M F Damen; Joos V Lebesque; Jan-Jakob Sonke
Journal:  Radiother Oncol       Date:  2013-04-23       Impact factor: 6.280

5.  Stereotactic body radiotherapy (SBRT) in central non-small cell lung cancer (NSCLC): solid evidence or "no-go"?

Authors:  Ursula Nestle; Corinne Faivre-Finn; Dirk DeRuysscher; Coen Hurkmans; Matthias Guckenberger; Jose Belderbos; Cecile le Pechoux
Journal:  Radiother Oncol       Date:  2013-09-07       Impact factor: 6.280

6.  Stereotactic body radiotherapy for lung tumors at the pulmonary hilum.

Authors:  Yoshiko Oshiro; Takashi Aruga; Koji Tsuboi; Kan Marino; Ryusuke Hara; Yasushi Sanayama; Jun Itami
Journal:  Strahlenther Onkol       Date:  2010-04-26       Impact factor: 3.621

Review 7.  The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?

Authors:  J Martin Brown; David J Carlson; David J Brenner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-02-01       Impact factor: 7.038

8.  Massive haemoptysis after radiotherapy in inoperable non-small cell lung carcinoma: is endobronchial brachytherapy really a risk factor?

Authors:  J A Langendijk; M K Tjwa; J M de Jong; G P ten Velde; E F Wouters
Journal:  Radiother Oncol       Date:  1998-11       Impact factor: 6.280

9.  Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications.

Authors:  Qiaoqiao Li; Cameron W Swanick; Pamela K Allen; Daniel R Gomez; James W Welsh; Zhongxing Liao; Peter A Balter; Joe Y Chang
Journal:  Radiother Oncol       Date:  2014-08-06       Impact factor: 6.280

Review 10.  Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review.

Authors:  Sashendra Senthi; Cornelis J A Haasbeek; Ben J Slotman; Suresh Senan
Journal:  Radiother Oncol       Date:  2013-02-22       Impact factor: 6.280
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.